School of Medicine
Showing 1-20 of 59 Results
-
Sally Arai
Associate Professor of Medicine (Blood and Marrow Transplantation and Cellular Therapy)
Current Research and Scholarly InterestsResearch interest in utilizing post-transplant adoptive cellular immunotherapy to reduce GVHD and relapse in patients with high risk hematologic malignancies.
-
Cameron Scott Bader
Postdoctoral Scholar, Bone Marrow Transplantation
BioMy research is focused on using preclinical models to develop novel therapies which improve outcomes for patients receiving allogeneic hematopoietic stem cell transplantation. Currently, my work aims to establish strategies to reduce the risk of relapse after allogeneic hematopoietic stem cell transplantation without exacerbating graft-versus-host disease or interfering with donor stem cell engraftment.
-
Sushma Bharadwaj, MD
Clinical Assistant Professor, Medicine - Blood & Marrow Transplantation
BioDr. Bharadwaj is fellowship-trained in blood and marrow transplantation, cellular therapy, hematology, and oncology. She is an instructor in the Stanford School of Medicine Department of Medicine, Division of Blood & Marrow Transplantation and Cellular Therapy.
Dr. Bharadwaj focuses her expertise on diagnosing and treating cancer in blood and bone marrow. For each patient, she develops a personalized, comprehensive, and compassionate care plan. In her diverse experience as a physician and scientist, she has served as an internal medicine doctor, hospitalist, hematologist, oncologist, and blood and marrow transplantation specialist. Dr. Bharadwaj has a degree in clinical research and is currently conducting clinical trials in transplant and cellular therapy.
She has participated in research studies of advances in therapy for chronic lymphocytic leukemia, melanoma, and breast cancer. She has co-authored articles published in Leukemia and Lymphoma and elsewhere. Topics include advances in cell transplantation. She also co-wrote the chapter on genome-driven personalized cancer therapy in the book Precision Medicine in Oncology.
Dr. Bharadwaj has made presentations at meetings of the American Society of Hematology, American Society of Clinical Oncology, and other associations.
Subjects include racial, demographic, and socioeconomic disparities in the treatment of patients with acute myeloid leukemia.
Dr. Bharadwaj is a member of the American Society for Transplantation and Cellular Therapy, American Society of Hematology, and American Society of Clinical Oncology. -
Saurabh Dahiya, MD, FACP
Associate Professor of Medicine (Blood and Marrow Transplantation and Cellular Therapy)
BioDr. Dahiya is a cancer specialist with board certification in internal medicine, hematology, and medical oncology. He is an Associate Professor at Stanford University School of Medicine and Clinical Director of Cancer Cell Therapy in the Stanford BMT and Cell Therapy division.
Dr. Dahiya strives to support each patient with a personalized and compassionate care plan that optimizes healing and quality of life.
Prior to joining Stanford, Dr. Dahiya was an associate professor of medicine at the Greenebaum Comprehensive Cancer Center at the University of Maryland School of Medicine, where he developed the Cellular Immunotherapy Program and served as the Director of Cellular Immunotherapy in leukemia and lymphoma.
Dr. Dahiya’s research focuses on cellular immunotherapy for hematologic malignancies. He has led and participated in several investigator-initiated studies and sponsored clinical trials with cell therapies (CAR-T, CAR-NK, TCR-T) for hematologic malignancies. His research group is also involved in various translational research activities for the standard of care and research CAR-T therapy. Dr. Dahiya’s group was the first group to show the role of fibrinogen in Neurotoxicity associated with CAR-T therapy. They showed vascular injury as manifested by high fibrinogen levels is associated with higher Neurotoxicity in patients who receive CAR-T therapy. More recently his group led a novel study of assessing the immune response to COVID-19 disease. They evaluated the immune response in critically ill and non-critically ill patients hospitalized with COVID-19 disease and showed a differential immune response between the groups. Dr. Dahiya’s group also showed and established poor immunogenicity of COVID-19 vaccines in CART recipients. As such, passive immunity and other strategies to address the issues of immunogenicity are being explored.
He has published more than 50 articles in peer-reviewed journals including the New England Journal of Medicine, Journal of Clinical Oncology, Blood, Blood Advances, Lancet, Leukemia Research, Neuro-Oncology, and many more. He reviews article submissions for the journals Critical Reviews in Oncology and Hematology, Thoracic Cancer, and Blood. He serves as the hematology lead editor for the journal Critical Reviews in Oncology and Hematology.
He has presented his research findings at conferences such as the annual meetings of the American Society of Hematology, American Society of Clinical Oncology, and American Society for Transplantation and Cell Therapy.
Dr. Dahiya is a member of the American Society of Hematology and the American Society of Transplantation and Cell Therapy. -
Matthew Frank
Assistant Professor of Medicine (Blood and Marrow Transplantation and Cellular Therapy)
BioDr. Matthew Frank, MD, PhD, is an Assistant Professor of Medicine in the Division of Blood and Marrow Transplantation and Cellular Therapy at Stanford University. Dr. Frank predominantly cares for patients with high-risk lymphoma and other blood cancers. He is a lead investigator of clinical trials evaluating the safety and effectiveness of cancer treatments called chimeric antigen receptor (CAR ) T therapy for patients with lymphomas and leukemias. Dr. Frank’s research focuses on developing methods to identify patients who are at high risk for relapse or developing side-effects after receiving CAR T therapy and to understand why these relapses and side-effects occur.
-
Hitomi Hosoya, MD, PhD
Instructor, Medicine - Blood & Marrow Transplantation
BioDr. Hosoya is fellowship-trained in blood and marrow transplantation, cellular therapy and hematology with the Stanford Medicine Cancer Center and an instructor at Stanford University in the Department of Medicine, Division of Blood & Marrow Transplantation and Cellular Therapy.
Her areas of expertise include transplantation, immunotherapies, and cellular therapies for patients with multiple myeloma and other plasma cell disorders. She diagnoses and treats a range of blood disorders from anemia and hemophilia to cancerous conditions like leukemia and multiple myeloma. For each patient, she prepares a personalized, comprehensive, and compassionate care plan.
Dr. Hosoya’s research is focused on improving cancer diagnostics and therapeutic decision-making in multiple myeloma. She is specifically interested in the genomics of multiple myeloma and its evolution over the course of the disease. Dr. Hosoya is studying the role of circulating tumor DNA (ctDNA) in patients with multiple myeloma and developing tools to detect and quantify tumors and their response to chemotherapy and immunotherapy, with a goal of informing personalized therapies. Dr. Hosoya demonstrated ctDNA is useful in detecting and monitoring tumor, and its prognostic value for patients undergoing CAR T-cell therapy in multiple myeloma. Her ongoing research is focused on applying cell-free DNA sequencing towards sensitive detection of copy number alterations, gene expression inferences, and understanding mechanisms of disease response and resistance in diverse therapies in multiple myeloma.
Dr. Hosoya is a member of the Society for Immunotherapy of Cancer, American Society of Clinical Oncology, American Society of Hematology, and the Japan Team Oncology Program.
